Literature DB >> 29369399

Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis.

Stephen D Ginsberg1,2,3,4, Melissa J Alldred1,2, Satya M Gunnam5, Consuelo Schiroli5, Sang Han Lee6, Susan Morgello7, Tracy Fischer5.   

Abstract

OBJECTIVE: CD16+ /CD163+ macrophages (MΦs) and microglia accumulate in the brains of patients with human immunodeficiency virus (HIV) encephalitis (HIVE), a neuropathological correlate of the most severe form of HIV-associated neurocognitive disorders, HIV-associated dementia. Recently, we found that some parenchymal microglia in brain of HIV+ subjects without encephalitis (HIV/noE) but with varying degrees of neurocognitive impairment express CD16 and CD163, even in the absence of detectable virus production. To further our understanding of microglial activation in HIV, we investigated expression of specific genes by profiling parenchymal microglia from archival brain tissue of patients with HIVE and HIV/noE, and HIV- controls.
METHODS: Single-population microarray analyses were performed on ∼2,500 laser capture microdissected CD163+ , CD16+ , or CD68+ MΦs/microglia per case, using terminal continuation RNA amplification and a custom-designed array platform.
RESULTS: Several classes of microglial transcripts in HIVE and HIV/noE were altered, relative to HIV- subjects, including factors related to cell stress, immune activation, and apoptosis. Additionally, several neurotrophic factors were reduced in HIV infection, suggesting an additional mechanism of neuropathogenesis. The majority of transcripts altered in HIVE displayed intermediate changes in HIV/noE.
INTERPRETATION: Our results support the notion that microglia contribute to the maintenance of brain homeostasis and their potential loss of function in the context of chronic inflammation contributes to neuropathogenesis. Furthermore, they indicate the utility of profiling MΦs/microglia to increase our understanding of microglia function, as well as to ascertain alterations in specific pathways, genes, and potentially, encoded proteins that may be amenable to targeted treatment modalities in diseases affecting the brain. Ann Neurol 2018;83:406-417.
© 2018 American Neurological Association.

Entities:  

Mesh:

Year:  2018        PMID: 29369399      PMCID: PMC5822676          DOI: 10.1002/ana.25160

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

1.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

2.  Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders.

Authors: 
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  Transcriptional profiling of small samples in the central nervous system.

Authors:  Stephen D Ginsberg
Journal:  Methods Mol Biol       Date:  2008

4.  Cytokine expression in the brain during the acquired immunodeficiency syndrome.

Authors:  W R Tyor; J D Glass; J W Griffin; P S Becker; J C McArthur; L Bezman; D E Griffin
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

5.  Apolipoprotein E suppresses the type I inflammatory response in vivo.

Authors:  Kamilah Ali; Melissa Middleton; Ellen Puré; Daniel J Rader
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

6.  Activation of microglia in HIV-1 infected brains is not dependent on the presence of HIV-1 antigens.

Authors:  S Weis; B Neuhaus; P Mehraein
Journal:  Neuroreport       Date:  1994-07-21       Impact factor: 1.837

7.  Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons.

Authors:  Hoon Ryu; Junghee Lee; Soren Impey; Rajiv R Ratan; Robert J Ferrante
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-16       Impact factor: 11.205

8.  Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis.

Authors:  M L Zhao; M O Kim; S Morgello; S C Lee
Journal:  J Neuroimmunol       Date:  2001-04-02       Impact factor: 3.478

9.  HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy.

Authors:  E H Corder; K Robertson; L Lannfelt; N Bogdanovic; G Eggertsen; J Wilkins; C Hall
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

Review 10.  RNA amplification strategies for small sample populations.

Authors:  Stephen D Ginsberg
Journal:  Methods       Date:  2005-11       Impact factor: 3.608

View more
  17 in total

1.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

2.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

Review 3.  HIV-associated neurodegeneration: exploitation of the neuronal cytoskeleton.

Authors:  Erin D Wenzel; Valeria Avdoshina; Italo Mocchetti
Journal:  J Neurovirol       Date:  2019-03-08       Impact factor: 2.643

4.  Age-Related Decrease in Tyrosine Hydroxylase Immunoreactivity in the Substantia Nigra and Region-Specific Changes in Microglia Morphology in HIV-1 Tg Rats.

Authors:  David R Goulding; Andrew Kraft; Peter R Mouton; Christopher A McPherson; Valeria Avdoshina; Italo Mocchetti; G Jean Harry
Journal:  Neurotox Res       Date:  2019-07-08       Impact factor: 3.911

Review 5.  Gene Expression: the Key to Understanding HIV-1 Infection?

Authors:  Melinda Judge; Erica Parker; Denise Naniche; Peter Le Souëf
Journal:  Microbiol Mol Biol Rev       Date:  2020-05-13       Impact factor: 11.056

6.  Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model.

Authors:  Christina Gavegnano; Woldeab Haile; Raj Koneru; Selwyn J Hurwitz; James J Kohler; William R Tyor; Raymond F Schinazi
Journal:  J Neurovirol       Date:  2020-09-08       Impact factor: 2.643

7.  Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.

Authors:  Jacqueline Rosenthal; William Tyor
Journal:  J Neurovirol       Date:  2019-03-13       Impact factor: 2.643

Review 8.  Disease-specific interactome alterations via epichaperomics: the case for Alzheimer's disease.

Authors:  Stephen D Ginsberg; Thomas A Neubert; Sahil Sharma; Chander S Digwal; Pengrong Yan; Calin Timbus; Tai Wang; Gabriela Chiosis
Journal:  FEBS J       Date:  2021-06-12       Impact factor: 5.622

9.  HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition.

Authors:  Susan Morgello; Etty P Cortes; Gary Gensler; Gregory Meloni; Michelle M Jacobs; Jacinta Murray; Valeriy Borukov; John F Crary
Journal:  AIDS       Date:  2021-07-15       Impact factor: 4.632

10.  Histone deacetylase 6 inhibition rescues axonal transport impairments and prevents the neurotoxicity of HIV-1 envelope protein gp120.

Authors:  Erin D Wenzel; Andrew Speidell; Sarah A Flowers; Chengbiao Wu; Valeria Avdoshina; Italo Mocchetti
Journal:  Cell Death Dis       Date:  2019-09-12       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.